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Abstract: A 78-year-old woman developed fatal endocarditis of her prosthetic aortic valve, caused by Bacteroides 
fragilis fragilis, and associated with ovarian carcinoma. The strain showed multiple antibiotic resistance, including 
resistance to  beta-lactam agents and combinations with beta-lactamase inhibitors. Seventeen previously described 
cases of endocarditis caused by Bacteroides spp. have been found in  the literature. The mean age of the 18 patients 
was 50.3 years, the gastro-intestinal tract was the most common site of associated disease, embolism occured in  ten 
cases and eight patients died. Previous isolates showed the antibiotic susceptibility customarily associated with the 
B. fragilis group. 
Anaerobic bacterial endocarditis has only occasionally 
been reported, and Bacteroides species were the most 
frequent causative agents (1, 2). Seventeen cases of 
B. fragilis group endocarditis have been reported to 
date (1 -7). The B. fragilis group strains responsible were 
found to be susceptible to most of the usual antibiotics 
active against these anaerobic bacteria. We report here 
a case of endocarditis caused by a multiply resistant 
strain of B. jugilisfrugilis. 
Case Report 
A 78-year-old woman was admitted to Broussais 
Hospital in March 1992 with major weight loss and 
abdominal pain. In 1980, a Starr valve had been 
implanted for severe aortic stenosis. At the time of 
admission, the patient had no fever or chills. Her blood 
pressure was 130/60 mm Hg and her pulse rate was 
72/min. Physical examination revealed pallor, hepato- 
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megaly and ascites. Chest X-ray revealed cardiac 
enlargement but the electrocardiogram was normal. 
An abdominal computed tomography scan disclosed 
irregular right ovarian hypertrophy. Paracentesis yielded 
non-purulent ascitic fluid with 1500 leukocytes/ 
mid (80% lymphocytes, 20% neutrophils) and 44 g/l 
protein. No abnormal cells were detected in the 
peritoneal fluid and culture for bacteria remained 
negative. Urine culture revealed bacteriuria (> lo5 
CFU/ml Escherichia coli) and the patient was given 
norfloxacin (400 mg b.i.d.) for seven days. Seventeen 
days after admission, the patient was referred to the 
department of surgery because of a small bowel 
occlusion. Her body temperature was 37.8"C but 
blood cultures were negative. Intravenous infusion of 
amoxicillin-clavulanic acid (1.2 g t.i.d.) was started 
immediately before the operation and continued 
for three days. Peritoneal neoplastic metastases were 
diagnosed and a palliative anastomosis between the 
ileum and the transverse colon was created. Pathologic 
analysis revealed an adenocarcinoma of the right ovary 
and Fallopian tube. Twenty-four hours after the amoxi- 
cillin-clavulanic acid treatment was discontinued, her 
body temperature was 39.0"C. Eight blood samples 
were cultured within 48 hours. Each was cultured in 
two media, one being intended for the isolation of 
strictly anaerobic bacteria (Anaer, Sanofi, Institut 
Pasteur, Paris, France). After a 3-day incubation, an 
anaerobic gram-negative rod was isolated in all 16 
cultures. The patient was initially treated with a 
combination of cefotaxime (2 g t.i.d., i.v.), sulbactam 
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(1 g t.i.d., i.v.) and amikacin 500 nig 18-hourly i.v.) for 
24 hours. Ornidazole was added 24 hours later (1 g per 
day i.v.). Because of the blood culture results and the 
persistence of fever, a laparotomy was again performed. 
There was no sign of intra-abdominal infection and the 
anastomosis was intact. Prosthetic valve endocarditis 
was suspected but echocardiography was not performed 
because of the patient’s poor clinical status. Her body 
temperature rose to 41.0OC and urine analysis gave a 
protein concentration of 1.2 g/l. The patient died eight 
hours later from cardiogenic shock. There were no 
vegetations at autopsy but two thrombi were found, 
covering and partly occluding the prosthetic valve. 
Microscopic exmination of the thrombi revealed 
neutrophils but Gram staining of material from the 
interior of the thrombus did not reveal any micro- 
organisms. After a 3-day incubation, however, a 
culture from this tissue yielded the same gram-negative 
anaerobic rod that had been found in the earlier blood 
cultures. Cultures of saniples of the prosthetic valve 
collected during autopsy also yielded the same 
microorganism. The strain was identified as B. frugilis 
fvagilis by conventional tests and with the API 20 A 
System (BioMkrieux, Marcy 1’Etoile 69280, France). 
Antibiotic susceptibility testing of this strain was 
performed by the disk diffusion method on Mueller 
Hinton agar supplemented with 5% horse blood, under 
anaerobic conditions. The strain was found to be 
susceptible to chloramphenicol, pristinaniycin, rifanipin 
and metronidazole, but resistant to benzyl penicillin, 
amoxicillin, amoxicillin-clavulanic acid, ticarcillin- 
clavulanic acid, piperacillin, piperacillin-tazobactam, 
cefoxitin, cefotaxime, cefotaxime-sulbactam, clinda- 
mycin, erythromycin, and tetracycline. The B. frugilis 
isolates from blood and thrombi cultures contained two 
variants with respect to carbapenem susceptibility. 
They were initially recognized as such on the basis of 
differences in the size of colonies and inhibition zones. 
The MICs of imipeneni were 32 p,g/ml for one variant 
and 128 p,g/ml for the other. Since production of 
the $A-encoded metallo-beta-lactamase (8) is res- 
ponsible for most, if not all, carbapenem resistance 
observed with clinical isolates of B. fragilis (9), we 
wondered whether this was also the case for the two 
variants. This was tested by DNA-DNA hybridization, 
using total DNA of each variant and a radio-labelled 
726-bp probe, spanning most of the $A gene and 
prepared by P C R  as described previously (10). DNA 
of both variants from blood and thrombi cultures did 
indeed hybridize with the probe. 
The molecular basis for the difference in the 
levels of carbapenem resistance has not been in- 
vestigated. A likely possibility, suggested by various 
mechanistic and epidemiological studies (9, 1 I) ,  would 
be that $A expression is driven by different promoters 
in the two variants. 
Discussion 
Endocarditis due to the B. fragilis group has rarely been 
reported (1-7). M the cases reported, including ours, 
are described in Table 1. The previous cases occured 
most often in elderly patients (mean age, 50.3 years; 
range, 6-78 years). Of the 18 patients (including the 
present case) 13 were males and 5 females. Six patients 
had had no known previous heart disease, nine had had 
previous valvular disease and two patients, including 
ours, had prostheses in situ. Embolism was observed in 
ten cases, probably because of production of heparinase 
by the B. fragilis group (1, 2). Eight patients died 
and ten were cured. Three cases were polymicrobial, 
including one case with S. uureus, E. coli and Enterococcus 
fueralis and two cases with anaerobic streptococci (1, 2). 
The portal of entry was most often the gastrointestinal 
tract (56%) and in other cases the oropharynx, the 
respiratory tract or the genital tract (1). B.frugilis group 
strains responsible for endocarditis were sensitive to 
the antibiotics usually active against this organism. 
Combined therapy was used in 16/18 patients and 
monotherapy with tetracycline was used in two patients 
who were cured. Cardiac surgery was necessary in one 
patient because of a severe aortic regurgitation. In our 
patient, endocarditis was caused by a strain resistant to 
a number of antibiotics, including cefoxitin, imipeneni 
and various combinations of antibiotics with beta- 
lactamase inhibitors. 
Antimicrobial resistance among the B. fragilis 
group has recently increased both in Europe (12-15) 
and the United States (16). The percentage of B.fvagilis 
resistant to clandaniycin ranges from 7 to 25% in 
Europe (12-15) and has been measured as 10% in 
the United States (16). The main mechanism for beta- 
lactam resistance is the production of beta-lactamases, 
including penicillinases, cephalosporinases and metallo- 
beta-lactamases which can hydrolyse imipenem (1 7). 
However, the incidence of resistance to cefoxitin was 
reported to be only 2 to 4% (1 4, 17). Most of the strains 
remain susceptible to the combinations amoxicillin- 
clavulanic acid, ampicillin-sulbactani, ticarcillin-clavu- 
lanic acid and piperacillin-tazobactam, with usually 
less than 3% resistance to these combinations (12, 16). 
The majority of beta-lactani-resistant strains remain 
susceptible to imipenem because it is intrinsically 
refractory to beta-lactamase degradation (16). Indeed, 
resistance of B. jagi lk  to imipenem has rarely been des- 
cribed (10, 12, 18-20) and usually occurs in less than 
3% ofall reported strains (12, 15, 16). Nevertheless, the 
percentage of resistant strains has recently increased, 
4 6  J o u r n a l  of  Cl in ica l  M i c r o b i o l o g y  a n d  In fec t ion ,  V o l u m e  1 N u m b e r  1 
Table 1 Reports of endocarditis due to Bacteroides fragilis. 
Case Age, Probable Underlying Prior heart Valvular 
No sex source condition disease location Complications Therapy Outcome Ref: 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
19, M IV heroin 
injection 
6, M GI tract 
Intravenous 
drug user 
None 
No 
No 
No 
No  
Arterioslerotic 
heart disease 
Rheumatic 
fever 
Arterioslerotic 
heart disease 
No  
Rheumatic 
fever 
Rheumatic 
fever 
Arterioslerotic 
heart disease 
Arterioslerotic 
heart disease 
Rheumatic 
fever 
No  
- 
Myocardial 
infarction 
Aortic valve 
slerosis 
Aortic Starr 
valve 
Tricuspid 
- 
- 
Mitral 
- 
- 
- 
- 
- 
- 
- 
- 
Left atrium 
Aortic 
M i t d  and 
aortic 
prosthesis 
- 
Aortic 
Aortic 
prosthesis 
Pulmonary 
embolism 
Heart failure 
Liver abscess 
Heart failure 
Penicillin, kanamycin Cure 
Cure 
Cure 
Death 
Cure 
Cure 
Cure 
Cure 
Death 
Death 
Death 
Death 
Death 
Cure 
Cure 
Death 
Cure 
Death 
Ampicillin, kanamycin 
21, F Septic 
abortion 
None Penicillin, streptomycin, 
chloramphenicol 
Cephalothin, kanamycin 
Tetracycline 
40. M Peritonitis None 
None 
Arterial embolism 
Arterial embolism 42, M Cholecystitis 
47, M Cutaneous ulcer H yperosmolar 
diabetes 
Arterial embolism Penicillin, 
chloramphenicol 
Penicillin, streptomycin, 
tetracycline, sulfamide 
Tetracycline 
52. M Periodontal abscess None None 
62, M Colonic 
diverticulosis 
65, M Aorto-duodenal 
fistula 
70, F Peritonitis 
Ketoacidosis Liver embolism 
Duodenal ulcer Heart failure 
Joint embolism 
Renal embolism 
Penicillin, streptomycin 
Cephalothin, 
chloramphenicol 
Penicillin, streptomycin, 
cephalothin 
Penicillin, kanamycin, 
cephalothin 
Renal 
insufficiency 
Parkinsonism Heart failure 71, F Cutaneous ulcer 
Emphysema Renal embolism 
Cerebral hemorrhage 
75, M Pneumonia 
56, M Appendicitis Heart failure, 
Pulmonary embolism 
Penicillin, streptomycin, 
erythomycin, vancomycin. 
chloramphenicol, 
tetracycline 
Clindamycin, 
metronidazole 
14 55, F Unknown 
15 14,M - 
Pulmonary 
fibrosis 
- 
None 
Heart failure Penicillin, gentamicin, 
cefuroxime, amikacin 
metronidazole. Surgery 
Ampicillin, gentamicin, 
cefoxitin, 
chloramphenicol 
Piperacilln, cefazolin, 
metronidazole, 
amoxicillin + clavulanic 
acid, imipenem 
16 54, M Colitis Septic shock, 
Myocardial abscess, 
Cerebral embolism 
78, M Colonic 
diverticulosis 
Zenker’s 
diveeticulum 
None 
Ovarian 
carcinoma 
78. F GI tract Heart failure Cefotaxime + sulbactam, 
ornidazole, amikacin 
“-”: not known or  not described in report. 
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particularly in Japan, rising from 2% in 1987 to 
5.9% in 1991 (21). The mechanism ofresistance to imi- 
penem is linked to synthesis of a metallo-beta-lactamase 
hydrolysing imipenem and most of the cephalosporins, 
including cephamycin derivatives, a t  a high rate (10, 
19-22). This imipenemase is not inhibited by beta- 
lactamase inhibitors, as was observed for our strain (10). 
We have suggested that a silent carbapenemase gene 
may be present in sensitive strains of B. fragilis and 
becomes phenotypically expressed after a one-step 
mutation under selective antibiotic pressure (10). 
The increased incidence of multiply resistant strains 
of B. fragilis presents a major therapeutic problem. The 
clinical use of non-beta-lactam agents should be 
encouraged, even though resistance to clindamycin has 
also recently increased (12-1 6) and chloraniphenicol 
lacks bactericidal activity against this species. In 
contrast, metronidazole, for which resistance has only 
been rarely reported (12, 19), was bactericidal against 
strains isolated from patients with endocarditis (4, 7). 
However, studies on the effectiveness of metronidazole 
as a single agent for treating B. fragilis group endo- 
carditis are lacking. Moreover, the number of reports 
of resistance to metronidazole is also increasing and 
the first instance of transferable low-level resistance 
has been described (17). Therefore, surgery consist- 
ing in the drainage and removal of necrotic tissues 
should be discussed as a possible treatment of intra- 
vascular anaerobic infections due to multiply resistant 
strains (23). The continuing increase in antimicrobial 
resistance among anaerobic bacteria, the B. jagilir 
group especially, requires the development of new anti- 
microbial agents for the treatment of severe infections. 
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